Short-course raltegravir intensification does not increase 2 long terminal repeat episomal HIV-1 DNA in patients on effective antiretroviral therapy.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Clinical Infectious Diseases

• Publication date

  2012-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/cid/cir721PMID 22016501PMCID PMC3283111
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response.

  2011cited by this paper
• Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy

  2010cited by this paper
• Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy.

  2010cited by this paper
• The Effect of Raltegravir Intensification on Low-level Residual Viremia in HIV-Infected Patients on Antiretroviral Therapy: A Randomized Controlled Trial

  2010cited by this paper
• HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects

  2010cited by this paper
• Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy

  2009cited by this paper
• ART Suppresses Plasma HIV-1 RNA to a Stable Set Point Predicted by Pretherapy Viremia

  2007cited by this paper

• Antiretroviral Therapy Intensification With Dolutegravir and/or Maraviroc Did Not Affect HIV-1 Cell-Associated DNA, RNA, and 2–LTR Circles Over 12 Weeks

  2025cites this paper
• Stationary distribution and extinction of a multi-stage HIV model with nonlinear stochastic perturbation

  2021cites this paper
• Prevalence and risk of residual viremia after ART in low- and middle-income countries

  2021cites this paper
• Differences in HIV Markers between Infected Individuals Treated with Different ART Regimens: Implications for the Persistence of Viral Reservoirs

  2020cites this paper
• Reduction of Immune Activation and Partial Recovery of Staphylococcal Enterotoxin B-Induced Cytokine Production After Switching to an Integrase Strand Transfer Inhibitor-Containing Regimen: Results from an Observational Cohort Study

  2019cites this paper
• Structure-guided drug design identifies a BRD4-selective small molecule that suppresses HIV.

  2019cites this paper
• Development of novel molecular and microfluidics tools for identification and characterization of latent HIV-1 reservoir

  2019cites this paper
• Episomal HIV-1 DNA and its relationship to other markers of HIV-1 persistence

  2018cites this paper
• Expanded cellular clones carrying replication-competent HIV-1 persist, wax, and wane

  2018cites this paper
• Influence of raltegravir intensification on viral load and 2-LTR dynamics in HIV patients on suppressive antiretroviral therapy.

  2017cites this paper
• Exploring viral reservoir: The combining approach of cell sorting and droplet digital PCR.

  2017cites this paper
• Characterization of inducible reservoirs of HIV-1

  2016cites this paper
• A Pilot Study of Raltegravir Plus Combination Antiretroviral Therapy in Early Human Immunodeficiency Virus Infection: Challenges and Lessons Learned

  2016cites this paper
• How to Define the Latent Reservoir: Tools of the Trade

  2016cites this paper
• A Novel in vitro Assay to Measure Stochastic Reactivation of HIV-1 from Resting CD4+ T Cells: Implications for Measuring the Size of the Latent Reservoir in Infected Patients

  2016cites this paper
• Prolonged persistence of a novel replication-defective HIV-1 variant in plasma of a patient on suppressive therapy

  2016cites this paper
• Towards an HIV-1 cure: measuring the latent reservoir.

  2015cites this paper
• Potential Implication of Residual Viremia in Patients on Effective Antiretroviral Therapy

  2015cites this paper
• The Tat Inhibitor Didehydro-Cortistatin A Prevents HIV-1 Reactivation from Latency

  2015cites this paper
• Early antiretroviral therapy with raltegravir generates sustained reductions in HIV reservoirs but not lower T-cell activation levels

  2015cites this paper
• Effect of therapeutic intensification followed by HIV DNA prime and rAd5 boost vaccination on HIV-specific immunity and HIV reservoir (EraMune 02): a multicentre randomised clinical trial.

  2015cites this paper
• Reply to Karch et al.

  2014cites this paper
• Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy

  2014cites this paper
• HIV cure research: advances and prospects.

  2014cites this paper
• Switch to raltegravir decreases soluble CD14 in virologically suppressed overweight women: the Women, Integrase and Fat Accumulation Trial

  2014cites this paper
• Dynamics of CD8 T-Cell Activation After Discontinuation of HIV Treatment Intensification

  2013influential citation
• Cell-associated HIV RNA: a dynamic biomarker of viral persistence

  2013cites this paper
• Do HIV-specific CTL continue to have an antiviral function during antiretroviral therapy? If not, why not, and what can be done about it?

  2013cites this paper
• Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV infection: a randomized, placebo-controlled trial.

  2013cites this paper
• Modelling HIV-1 2-LTR dynamics following raltegravir intensification

  2013cites this paper
• HIV-1 latency in proliferating T cells

  2013cites this paper
• Plasma Viremia and Cellular HIV-1 DNA Persist Despite Autologous Hematopoietic Stem Cell Transplantation for HIV-Related Lymphoma

  2013cites this paper
• Interferon alfa therapy: toward an improved treatment for HIV infection.

  2013cites this paper
• Developing strategies for HIV-1 eradication.

  2012cites this paper
• No Effect of Raltegravir Intensification on Viral Replication Markers in the Blood of HIV-1–Infected Patients Receiving Antiretroviral Therapy

  2012cites this paper
• antiretroviral therapy in resource-limited settings: adapting

  2012cites this paper
• Human Immunodeficiency Virus (HIV) Latency: The Major Hurdle in HIV Eradication

  2012cites this paper
• Current World Literature

  2003cites this paper